These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 16754809)
21. Viewpoint: Michele Brignole, MD, FESC. Some thoughts on unexplained syncope. Interview by Ingrid Torjesen, BSc. Brignole M Circulation; 2007 Mar; 115(10):f41-2. PubMed ID: 17361465 [No Abstract] [Full Text] [Related]
22. Finding value in the U.S. Food and Drug Administration's Fast Track program. Reichert JM; Rochon SL; Zhang BD Drug News Perspect; 2009; 22(1):53-8. PubMed ID: 19209299 [TBL] [Abstract][Full Text] [Related]
23. Sir Richard Sykes contemplates the future of the pharma industry. Interview by Rebecca N Lawrence. Lawrence RN Drug Discov Today; 2002 Jun; 7(12):645-8. PubMed ID: 12110238 [No Abstract] [Full Text] [Related]
24. New clinical trials policy at FDA. Vastag B Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196 [No Abstract] [Full Text] [Related]
25. The COPD Pipeline XIII. Gross NJ COPD; 2011 Dec; 8(6):464-5. PubMed ID: 22149408 [No Abstract] [Full Text] [Related]
26. Oncology's trials. Booth B; Glassman R; Ma P Nat Rev Drug Discov; 2003 Aug; 2(8):609-10. PubMed ID: 12908467 [No Abstract] [Full Text] [Related]
27. An audience with Thomas Lönngren. Interview by Asher Mullard. Lönngren T Nat Rev Drug Discov; 2010 Dec; 9(12):912. PubMed ID: 21119726 [No Abstract] [Full Text] [Related]
29. [Pharmacogenetic/regulatory aspects seen from the viewpoint of the industry]. Hansen L; Andersen D Ugeskr Laeger; 2005 May; 167(20):2160-4. PubMed ID: 15987073 [No Abstract] [Full Text] [Related]
30. Pediatric drug development in anesthesiology: an FDA perspective. Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624 [No Abstract] [Full Text] [Related]
31. Viewpoint: Marie Elsya Speechly-Dick, MD, MRCP. Interview by Ingrid Torjesen. Speechly-Dick ME Circulation; 2007 Nov; 116(21):f121-3. PubMed ID: 18025396 [No Abstract] [Full Text] [Related]
32. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Kesselheim AS; Mello MM Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677 [TBL] [Abstract][Full Text] [Related]
33. Mandatory comparator trials for therapeutically similar drugs: an assessment of the facts. Milne CP; Kaitin KI; Dimasi JA Am J Ther; 2007; 14(3):231-4. PubMed ID: 17515695 [No Abstract] [Full Text] [Related]
34. Evidence of comparative efficacy should have a formal role in European drug approvals. Sorenson C; Naci H; Cylus J; Mossialos E BMJ; 2011 Sep; 343():d4849. PubMed ID: 21896610 [No Abstract] [Full Text] [Related]
35. The marketplace can't give us the drug safety data we need. Avorn J MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636 [No Abstract] [Full Text] [Related]
37. Guinea-pigging: healthy human subjects for drug safety trials are in demand. But is it a living? Elliott C New Yorker; 2008 Jan; ():36-41. PubMed ID: 18265451 [No Abstract] [Full Text] [Related]
38. Researchers see a need for speed in EU trial approvals. Cressey D Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580 [No Abstract] [Full Text] [Related]
39. A look on the bright side. Nat Rev Drug Discov; 2005 Feb; 4(2):91. PubMed ID: 15756751 [No Abstract] [Full Text] [Related]
40. Closing the drug lag for new drug submission and review in Japan: An industry perspective. Poirier AF Clin Pharmacol Ther; 2015 Nov; 98(5):486-8. PubMed ID: 26239646 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]